TXG Earnings Date: Nov 5, 2026 (Estimated) — 10x Genomics, Inc.
NASDAQ · Healthcare · Health Information Services
Updated
When is TXG's next earnings date?
10x Genomics, Inc. (TXG) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.27 on revenue of $148.0M.
How did TXG do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), 10x Genomics, Inc. posted EPS of -$0.14 versus the -$0.24 estimate, a beat of 133.3%. Revenue was $151.0M against a $146.7M estimate. The stock's 1-day post-earnings move was +14.1%.
How much does TXG stock move after earnings?
TXG beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About 10x Genomics, Inc.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.24 | -0.14 | -133.33% | $151.0M | ✅ Beat | +14.10% | +27.52% | +37.39% |
| 2026-05-07 | Q1 2026 | -0.10 | -0.10 | +0.00% | $150.8M | ➖ Inline | -3.66% | -4.01% | +30.15% |
| 2026-02-12 | Q4 2025 | -0.10 | -0.13 | -30.00% | $166.0M | ❌ Miss | +3.48% | +7.82% | -4.68% |
| 2025-11-06 | Q3 2025 | -0.15 | -0.22 | -46.67% | $149.0M | ❌ Miss | +17.31% | +25.77% | +34.38% |
| 2025-02-12 | Q4 2024 | -0.11 | -0.40 | -263.64% | $165.0M | ❌ Miss | -0.50% | -3.67% | -13.83% |
| 2024-10-29 | Q3 2024 | -0.34 | -0.30 | +11.76% | $151.7M | ✅ Beat | +4.43% | +9.82% | -1.96% |
| 2024-08-08 | Q2 2024 | -0.47 | -0.32 | +31.91% | $153.1M | ✅ Beat | +4.50% | +15.81% | +11.61% |
| 2024-04-30 | Q1 2024 | -0.50 | -0.50 | +0.00% | $141.0M | ➖ Inline | -8.06% | -10.72% | -23.46% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $300.1M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product And Service Revenue | 49.7% | $149.1M | +2.7% | — | $137.8M | $145.2M | $148.0M |
| Consumables | 43.6% | $130.8M | +7.0% | $256.9M | $115.4M | $122.2M | $127.9M |
| Service | 3.6% | $10.7M | +26.0% | $13.0M | $7.7M | $8.5M | $8.1M |
| Instruments | 2.6% | $7.7M | -47.2% | $48.2M | $14.8M | $14.5M | $12.0M |
| Licensing And Royalty Revenue | 0.6% | $1.9M | -93.0% | — | $17.1M | $27.8M | $983K |
By region
Q2 FY26 · $233.1M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Americas | 36.5% | $85.0M | -19.9% | $87.2M | $90.6M | $106.2M | $79.9M |
| UNITED STATES | 35.2% | $82.1M | — | — | — | — | $77.2M |
| EMEA | 17.1% | $40.0M | +15.1% | $49.8M | $31.9M | $34.7M | $41.6M |
| CHINA | 6.4% | $15.0M | -35.4% | $14.6M | $16.9M | $23.2M | $15.2M |
| Asia-Pacific, Excluding China | 4.7% | $11.1M | +25.1% | $13.4M | $15.5M | $8.8M | $12.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.